Compare Eli Lilly And Co (LLY) vs PAGSEG Inc (PAGS) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

PAGS trades at $8.72, down 3.96% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The stock presents compelling value with a P/E of 6.17 and P/B of 0.87, supported by strong profitability metrics including 53.05% gross margin and 14.52% ROE. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while Q1 2026 showed a slight miss.

Analyst consensus remains bullish with 62.5% buy ratings and a $11.45 price target, suggesting 31% upside potential. Key risks include competitive pressures in Brazil's digital banking sector and macroeconomic sensitivity to interest rate cycles. The company maintains solid cash flow generation with $7.56B operating cash flow in 2025, supporting ongoing business expansion.